Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H24N6O2S2 |
Molecular Weight | 516.638 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(SC(=N1)C2=CC=CN=C2)C(=O)NC3=CC=CC=C3C4=CN5C(CN6CCOCC6)=CSC5=N4
InChI
InChIKey=LAMQVIQMVKWXOC-UHFFFAOYSA-N
InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
Molecular Formula | C26H24N6O2S2 |
Molecular Weight | 516.638 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20601277Curator's Comment: description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20601277
Curator's Comment: description was created based on several sources, including
SRT2104, also known as GSK2245840, is a novel, first in class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. SRT2104 in the phase II of clinical trial to treat type 2 diabetes mellitus and psoriasis also in the phase I for its use in case of colitis. Also was reported, that we report that SRT2104, penetrated the blood-brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25574479
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25574479
Curator's Comment: # Sirtris, a GlaxoSmithKline company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20601277 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
261.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762 |
3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered: |
SRT-2104 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1573 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762 |
3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered: |
SRT-2104 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762 |
3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered: |
SRT-2104 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Sirtuin 1 activator SRT2104 protects Huntington's disease mice. | 2014 Dec |
|
SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. | 2014 Oct |
|
The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans. | 2015 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26556603
oral administration (10–300 mg/kg/day; for five to 28 days)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24931715
C2C12 cells were treated with vehicle (0.1% DMSO) or 3 μM SRT2104 for 24 h. RelA/p65 protein levels were upregulated in C2C12 myoblasts in response to SRT2104 treatment. SRT2104 led to lower acetylation of RelA/p65 in C2C12 myoblasts, likely due to selective activation of SIRT1
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:32:29 GMT 2023
by
admin
on
Sat Dec 16 01:32:29 GMT 2023
|
Record UNII |
4521NR0J09
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SRT-2104
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY | |||
|
DTXSID00648729
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY | |||
|
25108829
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY | |||
|
1093403-33-8
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY | |||
|
300000041441
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY | |||
|
DB12186
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY | |||
|
4521NR0J09
Created by
admin on Sat Dec 16 01:32:29 GMT 2023 , Edited by admin on Sat Dec 16 01:32:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> ACTIVATOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |